Human metapneumovirus cDNA and Antigen

Human metapneumovirus (hMPV) is a respiratory virus that can cause upper and lower respiratory tract infections, such as the common cold, bronchiolitis, and pneumonia. hMPV is highly contagious and spreads through respiratory droplets from an infected person. It affects people of all ages, but is particularly common in young children, the elderly, and people with weakened immune systems. Symptoms of hMPV infection include runny nose, cough, sore throat, and fever. Treatment is primarily supportive, with measures such as rest, fluid intake, and over-the-counter medication to relieve symptoms. In severe cases, hospitalization may be necessary.

Human metapneumovirus (hMPV) antigen refers to a protein that is present on the surface of the virus and is recognized by the immune system. Antigens trigger an immune response, producing antibodies to fight the virus. Detecting hMPV antigens in a patient’s sample is an effective way to diagnose hMPV infection. Antigen tests for hMPV are widely available and are used in clinical settings to confirm the presence of the virus in patients with symptoms of hMPV-related respiratory infections.

The human metapneumovirus (hMPV) genome is the complete genetic material of the virus. It is composed of RNA, which codes for the production of essential proteins involved in the replication and pathogenesis of the virus. The hMPV genome is relatively stable, but small genetic variations can occur over time, leading to the evolution of different strains of the virus. Understanding the hMPV genome is crucial for developing effective antiviral therapies and vaccines against the virus. Analysis of the hMPV genome also helps in tracking the spread of the virus and in understanding how it evolves and adapts over time. The virus is composed of several proteins, including M2-1 and Nucleocapsid protein.

M2-1 is a transcriptional processivity factor that is involved in the regulation of viral RNA synthesis. It interacts with viral RNA and the RNA polymerase complex to ensure efficient viral replication. M2-1 is also essential to produce viral proteins and the assembly of new virions.

The Nucleocapsid protein of HMPV is responsible for encapsidating the viral RNA genome, forming the helical nucleocapsid structure. The protein is highly conserved among different strains of HMPV and is a potential target for developing antiviral drugs.

Understanding the structure and function of these proteins is crucial for developing effective treatments and vaccines for HMPV infections. Ongoing research on these proteins and other components of the HMPV virus will continue to provide insights into the biology of the virus and potential targets for therapeutic intervention.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E.coli expression Vector), which are ready for production of the recombinant proteins.